SCHEMBL3520286

SCHEMBL3520286

CCOC(=O)CNC(=O)c1c(O)c(-c2cnccn2)cc2nccnc12

nearest known ligand 0.57

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
EGLN3 Q9H6Z9 1/20 0.57
CASP1 P29466 1/20 0.39
CDC7 O00311 1/20 0.38
DBF4 Q9UBU7 1/20 0.38
ALDH1A1 P00352 4/20 0.38
HPGD P15428 3/20 0.38
LMNA P02545 2/20 0.38
HSD17B10 Q99714 2/20 0.38
SMN1; SMN2 Q16637 4/20 0.37
MAPT P10636 1/20 0.37
PPID Q08752 2/20 0.36
KMT2A Q03164 1/20 0.35
NPC1 O15118 4/20 0.35
RAB9A P51151 4/20 0.35
KDM4E B2RXH2 1/20 0.34
GAA P10253 1/20 0.34
TP53 P04637 1/20 0.34
GLA P06280 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3758545 0.86 EGLN3 (0.74) EGLN3
SCHEMBL3521075 0.84 EGLN3 (0.52) EGLN3CASP1ALDH1A1HPGDLMNA
SCHEMBL3527939 0.84 EGLN3 (0.50) EGLN3CASP1ALDH1A1HPGDLMNA
SCHEMBL3528917 0.84 EGLN3 (0.48) EGLN3CASP1ALDH1A1HPGDLMNA
SCHEMBL3543886 0.83 EGLN3 (0.48) EGLN3CASP1CDC7DBF4ALDH1A1
SCHEMBL3528513 0.81 EGLN3 (0.46) EGLN3CASP1ALDH1A1HPGDLMNA
SCHEMBL3521107 0.81 EGLN3 (0.44) EGLN3CASP1ALDH1A1HPGDLMNA
SCHEMBL3757510 0.80 EGLN3 (0.50) EGLN3ALDH1A1HPGDHSD17B10SMN1; SMN2
SCHEMBL3531139 0.80 EGLN3 (0.46) EGLN3CASP1ALDH1A1HPGDLMNA
SCHEMBL3520565 0.80 EGLN3 (0.50) EGLN3CASP1ALDH1A1HPGDLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101983384-A Prolyl hydroxylase inhibitors SMITHKLINE BEECHAM CORP 2011-03-02 CN disclosed
US-20100305133-A1 Prolyl Hydroxylase Inhibitors SMITHKLINE BEECHAM CORPORATION 2010-12-02 US disclosed
EP-2227770-A2 PROLYL HYDROXYLASE INHIBITORS GlaxoSmithKline LLC (US) 2010-09-15 EP disclosed
WO-2009073497-A2 PROLYL HYDROXYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2009-06-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305133-A1 Prolyl Hydroxylase Inhibitors HIF1AN, EGLN3, EGLN2 EGLN3 2/4885CASP1 2768/4885CDC7 3274/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.